Abstract 25P
Background
With the advent of novel antibody-drug conjugate (ADC), an emerging subgroup of human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized which may take advantage from the anti-tumor activity. We took advantage of Taiwan Cancer Registry (TCR) to evaluate the clinical presentations and prognostication for HER2-low breast cancer.
Methods
HER2-low breast cancers were defined operationally with HER2 immunohistochemistry (IHC) 1+ or 2+ with a negative fluorescence in situ hybridization (FISH) while HER2-zero defined with an IHC score 0. Breast cancer index cases (n=189465) from TCR between 2007 and 2017 were reduced to 133546 sides of breast cancer per subject. Clinical features such as IHC test, stage, grade and outcomes such as relapse-free and overall survival were compared between HER2-low and HER2-zero.
Results
The safety analysis group comprised 37195 HER2-negative breast cancers, including 14288 IHC 1+, 10486 FISH-negative, 8907 IHC 0 and 3323 IHC 2+/FISH-undetermined cases. Among HER2-negative breast cancers, the proportion of HER2-low and HER2-zero was 68.9% and 31.1%, respectively, after excluding HER2 ambiguity. Overall survival was 95.7% versus 95.9% for HER2-low and HER2-zero breast cancers, which was 94.1% and 94.7% for relapse-free survival. The distributions of pathological stages from 0 to IV were 6.7%, 41.5%, 38.5%, 13.1% and 0.3% for HER2-low and were 8.5%, 42.8%, 37.5%, 11% and 0.4% for HER2-zero breast cancers. Regarding estrogen receptor (ER) and progesterone receptor (PR) status, 87.6% and 80.9% of the HER2-low cases were ER+ and PR+ while 81.9% and 74.8% of the HER2-zero patients were ER+ and PR+. High or poorly differentiated grade was reported from 23.4% of HER2-low and 25.5% of HER2-zero breast cancers. The diagnosed age was 54 versus 54.3 between HER2-low and HER2-zero breast cancers (P=0.02).
Conclusions
HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LMT.
Funding
Melissa Lee Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract